Literature DB >> 26597610

Common gamma chain cytokines in combinatorial immune strategies against cancer.

Stephanie R Pulliam1, Roman V Uzhachenko2, Samuel E Adunyah3, Anil Shanker4.   

Abstract

Common γ chain (γC) cytokines, namely IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 are important for the proliferation, differentiation, and survival of lymphocytes that display antitumor activity, thus stimulating considerable interest for the use of cytokines in cancer immunotherapy. In this review, we will focus on the γC cytokines that demonstrate the greatest potential for immunotherapy, IL-2, IL-7, IL-15, and IL-21. We will briefly cover their biological function, potential applications in cancer therapy, and update on their use in combinatorial immune strategies for eradicating tumors and hematopoietic malignancies.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer immunotherapy; Gamma chain cytokines; Hematopoietic malignancies; Immunostimulation; Solid cancers

Mesh:

Substances:

Year:  2015        PMID: 26597610      PMCID: PMC4710466          DOI: 10.1016/j.imlet.2015.11.007

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  162 in total

1.  Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.

Authors:  Marc Buyse; Pierre Squifflet; Beverly J Lange; Todd A Alonzo; Richard A Larson; Jonathan E Kolitz; Stephen L George; Clara D Bloomfield; Sylvie Castaigne; Sylvie Chevret; Didier Blaise; Dominique Maraninchi; Kathryn J Lucchesi; Tomasz Burzykowski
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

2.  The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.

Authors:  Chiara Catania; Michela Maur; Rossana Berardi; Andrea Rocca; Anna Maria Di Giacomo; Gianluca Spitaleri; Cristina Masini; Chiara Pierantoni; Reinerio González-Iglesias; Giulia Zigon; Annaelisa Tasciotti; Leonardo Giovannoni; Valeria Lovato; Giuliano Elia; Hans D Menssen; Dario Neri; Stefano Cascinu; Pier Franco Conte; Filippo de Braud
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

Review 3.  Interleukin-15 biology and its therapeutic implications in cancer.

Authors:  Jason C Steel; Thomas A Waldmann; John C Morris
Journal:  Trends Pharmacol Sci       Date:  2011-10-25       Impact factor: 14.819

4.  IL-7 enhances the survival and maintains the size of naive T cells.

Authors:  J C Rathmell; E A Farkash; W Gao; C B Thompson
Journal:  J Immunol       Date:  2001-12-15       Impact factor: 5.422

5.  IFNγ in combination with IL-7 enhances immunotherapy in two rat glioma models.

Authors:  Sara Fritzell; Sofia Eberstål; Emma Sandén; Edward Visse; Anna Darabi; Peter Siesjö
Journal:  J Neuroimmunol       Date:  2013-03-23       Impact factor: 3.478

6.  Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1.

Authors:  Joseph T Opferman; Anthony Letai; Caroline Beard; Mia D Sorcinelli; Christy C Ong; Stanley J Korsmeyer
Journal:  Nature       Date:  2003-12-11       Impact factor: 49.962

7.  Interleukin-21 has activity in patients with metastatic melanoma: a phase II study.

Authors:  Teresa M Petrella; Richard Tozer; Karl Belanger; Kerry J Savage; Ralph Wong; Michael Smylie; Suzanne Kamel-Reid; Victor Tron; Bingshu E Chen; Naomi N Hunder; Linda Hagerman; Wendy Walsh; Elizabeth A Eisenhauer
Journal:  J Clin Oncol       Date:  2012-08-20       Impact factor: 44.544

8.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Authors:  Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2005-10-03       Impact factor: 14.307

Review 9.  Chronic inflammation and cytokines in the tumor microenvironment.

Authors:  Glauben Landskron; Marjorie De la Fuente; Peti Thuwajit; Chanitra Thuwajit; Marcela A Hermoso
Journal:  J Immunol Res       Date:  2014-05-13       Impact factor: 4.818

10.  Interleukin-7 receptor-α gene mutations are not detected in adult T-cell acute lymphoblastic leukemia.

Authors:  Uri Rozovski; Ping Li; David Harris; Maro Ohanian; Hagop Kantarjian; Zeev Estrov
Journal:  Cancer Med       Date:  2014-03-26       Impact factor: 4.452

View more
  21 in total

1.  LYG1 exerts antitumor function through promoting the activation, proliferation, and function of CD4+ T cells.

Authors:  Huihui Liu; Yanfei Zhang; Zhengyang Liu; Pingzhang Wang; Xiaoning Mo; Weiwei Fu; Wanchang Liu; Yingying Cheng; Wenling Han
Journal:  Oncoimmunology       Date:  2017-03-07       Impact factor: 8.110

2.  IL-2 And IL-15 Induced NKG2D, CD158a and CD158b Expression on T, NKT- like and NK Cell Lymphocyte Subsets from Regional Lymph Nodes of Melanoma Patients.

Authors:  Ana Vuletić; Irena Jovanić; Vladimir Jurišić; Zorka Milovanović; Srđan Nikolić; Igor Spurnić; Gordana Konjević
Journal:  Pathol Oncol Res       Date:  2018-06-11       Impact factor: 3.201

3.  Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein.

Authors:  Spencer Ng; Jiusheng Deng; Raghavan Chinnadurai; Shala Yuan; Andrea Pennati; Jacques Galipeau
Journal:  Cancer Res       Date:  2016-08-03       Impact factor: 12.701

4.  Interleukin-23 engineering improves CAR T cell function in solid tumors.

Authors:  Xingcong Ma; Yang Xu; Peishun Shou; Christof Smith; Yuhui Chen; Hongwei Du; Chuang Sun; Nancy Porterfield Kren; Daniel Michaud; Sarah Ahn; Benjamin Vincent; Barbara Savoldo; Yuliya Pylayeva-Gupta; Shuqun Zhang; Gianpietro Dotti
Journal:  Nat Biotechnol       Date:  2020-02-03       Impact factor: 54.908

Review 5.  Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer.

Authors:  Allison M Campbell; Roy H Decker
Journal:  Transl Lung Cancer Res       Date:  2017-04

Review 6.  IL-2 and Beyond in Cancer Immunotherapy.

Authors:  John M Wrangle; Alicia Patterson; C Bryce Johnson; Daniel J Neitzke; Shikhar Mehrotra; Chadrick E Denlinger; Chrystal M Paulos; Zihai Li; David J Cole; Mark P Rubinstein
Journal:  J Interferon Cytokine Res       Date:  2018-02       Impact factor: 2.607

7.  IRF4 Modulates CD8+ T Cell Sensitivity to IL-2 Family Cytokines.

Authors:  Su Huang; Yingjia Shen; Duy Pham; Li Jiang; Zheng Wang; Mark H Kaplan; Guangjun Zhang; Jie Sun
Journal:  Immunohorizons       Date:  2017-08-14

8.  Butyrate regulates the expression of inflammatory and chemotactic cytokines in human acute leukemic cells during apoptosis.

Authors:  Stephanie R Pulliam; Samuel T Pellom; Anil Shanker; Samuel E Adunyah
Journal:  Cytokine       Date:  2016-05-30       Impact factor: 3.861

9.  Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect.

Authors:  Martin Felices; Alexander J Lenvik; Ron McElmurry; Sami Chu; Peter Hinderlie; Laura Bendzick; Melissa A Geller; Jakub Tolar; Bruce R Blazar; Jeffrey S Miller
Journal:  JCI Insight       Date:  2018-02-08

Review 10.  Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.

Authors:  Shaowei Zhu; Yuanyi Liu; Paul C Wang; Xinbin Gu; Liang Shan
Journal:  Biomed Res Int       Date:  2017-06-29       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.